within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A16A_OtherAlimentaryTractAndMetabolismProducts.A16AB13_AsfotaseAlfa;

model AsfotaseAlfa
  extends Pharmacolibrary.Drugs.ATC.A.A16AB13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A16AB13</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Asfotase alfa is a recombinant human tissue-nonspecific alkaline phosphatase enzyme replacement therapy indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP), a rare genetic disorder characterized by defective bone mineralization due to deficient activity of alkaline phosphatase. It is an approved medication for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in pediatric and adult patients with hypophosphatasia, based on population PK studies and summary data from clinical trials.</p><h4>References</h4><ol><li><p>Pan, WJ, et al., &amp; Seefried, L (2021). Pharmacokinetics of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia. <i>Journal of clinical pharmacology</i> 61(10) 1334–1343. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1870&quot;>10.1002/jcph.1870</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33822385/&quot;>https://pubmed.ncbi.nlm.nih.gov/33822385</a></p></li><li><p>Dahir, KM, et al., &amp; Pan, WJ (2024). Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. <i>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</i> 39(10) 1412–1423. DOI:<a href=&quot;https://doi.org/10.1093/jbmr/zjae128&quot;>10.1093/jbmr/zjae128</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39135540/&quot;>https://pubmed.ncbi.nlm.nih.gov/39135540</a></p></li><li><p>Whyte, MP, et al., &amp; Landy, H (2012). Enzyme-replacement therapy in life-threatening hypophosphatasia. <i>The New England journal of medicine</i> 366(10) 904–913. DOI:<a href=&quot;https://doi.org/10.1056/NEJMoa1106173&quot;>10.1056/NEJMoa1106173</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22397652/&quot;>https://pubmed.ncbi.nlm.nih.gov/22397652</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end AsfotaseAlfa;
